Vietnam Diagnostic Tests Market to Reach USD 3.13 Billion by 2032, Growing at a CAGR of 8.59% During 2026–2032

The Vietnam diagnostic tests market was valued at USD 1.68 billion in 2025 and is projected to increase to USD 1.91 billion in 2026 and further to USD 3.13 billion by 2032. The industry is anticipated to achieve a CAGR of 8.59% during 2026–2032. This steady expansion reflects growing healthcare investments alongside expanding access to medical services and an increasing nationwide focus on preventive screening.

Additionally, the country's changing disease landscape is driving significant long-term clinical testing volumes. The rising prevalence of complex chronic diseases, including widespread diabetes and hypertension, requires regular diagnostics and follow-up patient monitoring. Furthermore, a heavy burden of persistent communicable conditions, such as high-incidence tuberculosis and seasonal outbreaks of dengue fever, necessitates continuous diagnostic screening and robust disease surveillance across all healthcare sectors.

In parallel, immunoassay-based diagnostic tests have emerged as the leading technology category due to their high clinical accuracy, rapid turnaround times, and extensive cost efficiency. Consequently, infectious diseases dominate the application spectrum because of large-scale national screening mandates and ongoing public health outbreak-control activities. These established workflows are heavily supported by expanding medical facilities and the clinical integration of pathology and pathogen detection solutions.

Moreover, the industry is actively embracing advanced research methodologies, including digital health tracking and next-generation clinical platforms. The domestic ecosystem is experiencing a shift toward laboratory automation and electronic health systems to optimize diagnostic accuracy and reduce turnaround times. As a result, recent developments, such as the deployment of artificial intelligence-powered imaging tools, are significantly expanding complex diagnostic capabilities and boosting service quality.

Consequently, despite structural challenges related to uneven regional infrastructure and high medical equipment costs, market players are capitalizing on substantial opportunities through strategic technological upgrades. As a result, recent legislative updates like the Law on Medical Examination and Treatment are standardizing healthcare connectivity and accelerating laboratory modernization, further states the research report, “Vietnam Diagnostic Tests Market Analysis, 2026”.

Vietnam Diagnostic Tests Market Highlights

The Vietnam diagnostic tests market was valued at USD 1.68 billion in 2025 and is projected to reach USD 3.13 billion by 2032, driven by an expanding burden of chronic conditions and increased utilization of screening solutions. Shifting toward preventive care enables healthcare providers to achieve early disease identification, better risk assessment, and improved patient treatment management.
The market is anticipated to expand at a CAGR of 8.59% during the forecast period of 2026–2032, heavily supported by strong institutional frameworks and modernization investments. This trajectory is further reinforced by policy-led initiatives like the Law on Medical Examination and Treatment (2024) and Circular 38/2024/TT-BYT, which focus on expanding regional testing capacity.
Immunoassay-Based Diagnostic Tests lead the industry by test technology, accounting for approximately 30% of total market revenue in 2026, remaining vital due to their scalability and high accuracy across routine screenings. The segment benefits extensively from cost efficiency, making critical testing for diseases like hepatitis B, hepatitis C, and HIV highly accessible.
Infectious Diseases dominate the application spectrum with an estimated 32% share in 2026, propelled by persistent outbreak cycles of dengue fever, measles, and hand, foot, and mouth disease. The segment's leadership is strongly backed by extensive national surveillance programs and high tuberculosis screening demands, given Vietnam's status as a high TB-burden nation.
The top five companies collectively account for approximately 39% of the total market share in 2026, indicating a moderately fragmented industry structure where leading international contract manufacturers compete through digital integration. Top-tier market participants are actively investing in premium diagnostic platforms, AI-enabled endoscopy, and next-generation photon-counting CT imaging systems to expand their domestic footprints.

Vietnam Diagnostic Tests Market Segmentation

By Test Technology
- Immunoassay-Based Diagnostic Tests
- Molecular Diagnostic Tests (PCR, NAAT, FISH, NGS)
- Clinical Chemistry Tests
- Hematology Tests
- Microbiology & Culture-Based Tests
- Coagulation Tests
- Others
By Disease Application
- Infectious Diseases (Hepatitis, TB, HIV, Dengue)
- Oncology
- Cardiovascular Diseases
- Metabolic & Endocrine Disorders (diabetes, thyroid)
- Women’s Health & Prenatal Testing
- Neurology, Autoimmune & Other Chronic Conditions
By End User
- Hospital-Based Laboratories (public & private hospitals)
- Independent Diagnostic Laboratories
- Clinics & Physician Offices
- Home Care & Self-Testing (POCT-based use)
- Public Health & Government Laboratories
- Research & Academic Laboratories
By Region
- Northern Vietnam
- Central Vietnam
- Southern Vietnam